Rosenstock J, Blonde L, Aroda VR, Frias J, et al. Switching to iGlarLixi vs Continuation of Daily or Weekly GLP-1 RA in
Insufficiently Controlled Type 2 Diabetes: A LixiLan-G Trial Subgroup Analysis by
HbA1c and GLP-1 RA Use at Screening. Diabetes Obes Metab 2021 Feb 10. doi: 10.1111/dom.14345.
PMID: 33565209